Fig. 7

Targeting CB2 delays tumor progression. a CB2 antagonists inhibit tumor growth. Six-week-old mice were subcutaneously inoculated with MC-38 tumors and treated with CB2 antagonists, AM-630 (0.3 mg kg⁻¹ d⁻¹, i.p.) or JTE-907 (0.5 mg kg⁻¹ d⁻¹, i.p.). The tumor volume was measured dynamically. The data represent means ± s.e.ms. (n = 10, ***P < 0.005, Student’s t-test). b CB2 antagonists improve the survival of tumor-bearing mice. The MC-38 tumor-bearing mice were described in a. The survival time was recorded. The experiment was repeated twice (n = 10, **P < 0.01, Gehan-Breslow-Wilcoxon test). c The MMTV-PyMT mice were treated with PBS or AM630 (0.3 mg kg⁻¹ d⁻¹, i.p.) starting from 6 weeks old and sacrificed at 14 weeks old. The representative gross morphology of primary mammary tumors and lung metastasis were displayed. The size of the primary mammary tumors were calculated. (n = 6, ***P < 0.005, Student’s t-test). d Tumor lesions in lungs from the mice described in c (n = 6, ***P < 0.005, Student’s t-test). Scale bars, 200 μm